Abstract 313P
Background
Outcome of recurrent/metastatic gynaecological cancer has drastically improved with introduction of PARP inhibitors and immunotherapy; but use of these drugs in routine practice is very difficult due to access barrier and high cost in developing countries. We aimed to present response, treatment outcome and safety of oral metronomic chemotherapy (OMCT) in a financially challenged, resource limited population.
Methods
This is a retrospective study on patients with advanced gynaecological cancer treated at Chittaranjan National Cancer Institute, Kolkata-West Bengal from 2021-2023; with either split course tablet Cyclophosphamide (50 mg once daily orally for 21 days) and tablet Capecitabine (500 mg twice daily orally continuous) or fixed dose combination (1800 mg +80 mg orally for 14 days in every 21 days) till disease progression or unacceptable toxicities. All data captured from medical records of hospital up till June 2023. Toxicity data was reported as per CTCAE V5 and progression free survival (PFS) was estimated using Kaplan Meier methods.
Results
Among 32 screened patients; 9 excluded due to noncompliance. 24 patients were analysed with median age at diagnosis of 56 years (IQ range 44-75). 16 (67%) patients were stage IV diseases with ECOG performance status 3. Ovarian and cervical cancer were 80% and 20% respectively; among them 16 (67%) patients were platinum refractory. 42% patients received three prior lines of chemotherapy before OMCT. Spit course versus fixed dose were given 67% versus 33% of population with best response were CR in 12%, PR 67%, SD 21% as per RECIST v1.1. Most common toxicities were Grade I anaemia (54%), grade I CINV (46%), grade I fatigue (42%) and grade I neutropenia (21%). 25% of patients were offered next line systemic therapy after progression. Median PFS was 9 months (95% CI 5.2-12.7) of entire cohort. Cox regression analysis identified median PFS of 12 months (95% CI 6.2-17.7) among platinum refractory group.
Conclusions
This OMCT was well-tolerated, affordable regimen with durable clinical response and survival outcome in recurrent refractory advanced gynaecological cancer and can be offered among patients in resource limited centres.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract